Skip to content

Quantification of Brain and Kidney Perfusion Before, During, and After Hypothermia Treatment in Neonates With Perinatal Asphyxia Using Contrast-enhanced Ultrasound

Quantification of Brain and Kidney Perfusion Before, During, and After Hypothermia Treatment in Neonates With Perinatal Asphyxia Using Contrast-enhanced Ultrasound

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06611254
Enrollment
20
Registered
2024-09-24
Start date
2024-06-24
Completion date
2027-12-01
Last updated
2024-09-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gestational Age Min. 36SSW, Hypothermia Treatment, Perinatal Asphyxia

Brief summary

In this clinical study vascular dynamics in the neonatal brain and kidney will be monitored by CUES and ULM before, during and after hypothermia treatment in neonates with asphyxia.

Detailed description

Perinatal asphyxia (PA) is the reduced supply of oxygen to vital organs during or immediately after birth. PA is one of the most common causes of neonatal mortality in full-term infants worldwide and of hypoxic-ischemic encephalopathy (HIE) with subsequent neurological deficits (spastic cerebral palsy). In addition to brain damage, perinatal asphyxia often leads to dysfunction of other organs. It is not uncommon for this to be accompanied by transient renal failure. Hypothermia treatment is an established therapeutic measure for neuroprotection in clinical indications of HIE. This involves lowering the core body temperature of affected children to 33.5°C for 72 hours. The therapeutic effect is thought to be due to multifactorial mechanisms, including a reduction in endothelial dysfunction, reduced excretion of free radicals and attenuation of the inflammatory cascade. In the guidelines for hypothermia treatment in neonatal asphyxia, regular ultrasound examinations are prescribed to clarify damage to the central nervous system (CNS) before, during and after hypothermia treatment.1 In infants, transfontal ultrasound makes it possible to visualize brain structures, vessels and their flow velocities. The intravenous use of ultrasound contrast enhancers as an aid also opens up the possibility of recording the tissue perfusion of the CNS and kidneys, including the smallest vessels.8 This could provide significantly more information compared to conventional methods and expand our knowledge of the pathophysiology and individual status of tissue perfusion in patients. For example, two studies at Erlangen University Hospital have successfully used contrast-enhanced ultrasound (CEUS) with the contrast agent known as SonoVue® to visualize postoperative perfusion of the brain after pediatric cardiac surgery. In this clinical study, the new CEUS measurement and imaging technique will be used before, during and after hypothermia treatment in neonates with asphyxia. A contrast agent (SonoVue®) will be administered during the routine ultrasound examination and improved tissue visualization will be achieved. The aim is to gain new insights into brain and kidney perfusion as part of the treatment and to better assess the extent of organ damage in the individual patient through more specific vascular imaging. Improved visualization and assessment of the end-stream area will provide information on processes that promote the development of HIE and renal failure. Finally, the aim is to compare diagnostic and prognostic methods with the currently recommended measures. The CEUS is to be examined as a possible diagnostic imaging tool and possibly a supplement to existing diagnostic methods.

Interventions

CEUS is a contrast based ultrasound technique and ULM (Ultrasound Localization Microscopy) is a post-processing bioinformatical method to quantify microvascular architecture and perfusion dynamics.

Sponsors

University of Erlangen-Nürnberg Medical School
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL

Inclusion criteria

* Fulfillment of the inclusion criteria for hypothermia treatment according to the AWMF guideline * Severe acidosis (pH ≤7.0 or a base deficit ≥16 mmol/l) in umbilical cord blood or a blood sample from the first hour of life, and * clinical signs of moderate or severe encephalopathy (severity grade 2 or 3 according to Sarnat & Sarnat), and * postnatal age ≤6h, and * gestational age ≥36 weeks' gestation * Consent of the parents/legal guardians * Time 1 (before the start of hypothermia treatment) * Informing the parents/legal guardians present on site despite an emotionally stressful situation with high individual benefit for the patient * If only one parent is present and able to provide information, their consent is sufficient - the second parent is informed repeatedly when they regain the ability to provide information * Information adapted to the emergency situation, addressing the personal situation and comprehensible presentation of the plan * Time 2 (during hypothermia treatment) --\>Offer of a further informative discussion/repeated explanation with the parents/legal representatives before the second measurement in order to answer any questions that may have arisen * Suitable acoustic window * Availability of the qualified examiner

Exclusion criteria

* Lack of consent of at least one parent * Pre-existing brain malformations * Absence of the competent examiner

Design outcomes

Primary

MeasureTime frameDescription
Visualization and quantification of of renal perfusion with CEUSbefore(T1, within the first 6hours of life), during hypothermia treatment(T2, 6-78hours of life), after treatment (T3, within first week of life)CEUS imaging for renal perfusion in asphyxia
CEUS Measurement3before(T1, within the first 6hours of life), during hypothermia treatment(T2, 6-78hours of life), after treatment (T3, within first week of life)WiAUC (Wash-in Area Under the Curve (AUC(TI: TTP)))
CEUS Measurement4before(T1, within the first 6hours of life), during hypothermia treatment(T2, 6-78hours of life), after treatment (T3, within first week of life)RT (Rise Time)
CEUS Measurement5before(T1, within the first 6hours of life), during hypothermia treatment(T2, 6-78hours of life), after treatment (T3, within first week of life)mTT (mean Transit Time local) (mTT-TI))
CEUS Measurement6before(T1, within the first 6hours of life), during hypothermia treatment(T2, 6-78hours of life), after treatment (T3, within first week of life)TTP (Time to Peak)
CEUS Measurement7before(T1, within the first 6hours of life), during hypothermia treatment(T2, 6-78hours of life), after treatment (T3, within first week of life)WiR (Wash-in-Rate )
CEUS Measurement8before(T1, within the first 6hours of life), during hypothermia treatment(T2, 6-78hours of life), after treatment (T3, within first week of life)WiPI (Wash-in Perfusion Index (WiAUC/RT))
CEUS Measurement9before(T1, within the first 6hours of life), during hypothermia treatment(T2, 6-78hours of life), after treatment (T3, within first week of life)WoAUC (Wash-out AUC (AUC(TTP:TO)))
CEUS Measurement10before(T1, within the first 6hours of life), during hypothermia treatment(T2, 6-78hours of life), after treatment (T3, within first week of life)WiWoAUC (Wash-in- und Wash-out-AUC (WiAUC+WoAUC))
CEUS Measurement12before(T1, within the first 6hours of life), during hypothermia treatment(T2, 6-78hours of life), after treatment (T3, within first week of life)WOR (Wash-out-Rate) QOF (Quality Of Fit between the echo-power signal and f(t)
CEUS Measurement13before(T1, within the first 6hours of life), during hypothermia treatment(T2, 6-78hours of life), after treatment (T3, within first week of life)QOF (Quality Of Fit between the echo-power signal and f(t)
Near-infrared spectroscopybefore(T1, within the first 6hours of life), during hypothermia treatment(T2, 6-78hours of life), after treatment (T3, within first week of life)Near-infrared spectroscopy Non-invasive measurement of oxygen saturation in tissue using a probe that is attached to the head.62 This procedure is already firmly established in the field of pediatric surgery and pediatric cardiology interventions at the University Hospital Erlangen. The probe is attached before the start of the first measurement time point and removed after the end of the third measurement time point. There is no risk of side effects.
Visualization and quantification of cerebral perfusion with CEUSbefore(T1, within the first 6hours of life), during hypothermia treatment(T2, 6-78hours of life), after treatment (T3, within first week of life)CEUS imaging for cerebral perfusion in asphyxia
CEUS Measurement11before(T1, within the first 6hours of life), during hypothermia treatment(T2, 6-78hours of life), after treatment (T3, within first week of life)FT (Fall Time - (TO-TTP))
CEUS Time intensity curvesbefore(T1, within the first 6hours of life), during hypothermia treatment(T2, 6-78hours of life), after treatment (T3, within first week of life)All CEUS outcomes will be generated in order to achieve time intensity curves in contrast enhanced ultrasound analysis
CEUS Measurement1before(T1, within the first 6hours of life), during hypothermia treatment(T2, 6-78hours of life), after treatment (T3, within first week of life)PE (Peak-Enhancement)
CEUS Measurement2before(T1, within the first 6hours of life), during hypothermia treatment(T2, 6-78hours of life), after treatment (T3, within first week of life)WiAUC (Wash-in Area Under the Curve (AUC(TI: TTP)))

Secondary

MeasureTime frameDescription
Neurological status assessment (Bayley Score)Month of life: 3-4 and 6-24Neurological status of the patients will be assessed by the score Bayley Scales of Infant and Toddler Development
MRI imaging in asphyxiaonce within first two years of lifeMRI Weeke Score
Comparison of the CEUS time-intensity curve between three timepointsT1,T2, T3CEUS curve at T1,T2, T3
Assessment of blood LactateT1, T2, T3Lactate (mmol/l)
EEG signs of seizuresT1 -T3 and through study completionNumber (n) of ETPs in EEG
EEG activityT1 -T3 and through study completionfrequency EEG (Hz)
Assessment of renal function GFRT1 -T3 and through study completion, an average of 3 yearsGFR (ml/min/1,73 m2)
Assessment of renal function ureaT1 -T3 and through study completion, an average of 3 yearsurea (mg/dl)
Assessment of renal function urinary statusT1 -T3 and through study completionstandardized urinary status
Assesment of renal function kreatininekinaseT1, T2, T3kreatininekinase (U/l)
Assessment of metabolic LDHT1, T2, T3LDH (U/l)
CEUS and NIRST1,T2,T3Correlation coefficient (R) between CEUS curve and NIRS

Countries

Germany

Contacts

Primary ContactFerdinand Knieling, MD
ferdinand.knieling@uk-erlangen.de0049 9131 85 33118
Backup ContactGregor Hanslik, MD
gregor.hanslik@uk-erlangen.de0049 9131 85 33118

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026